Science Applications International Corp 10-Q

Item 1. Financial Statements SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Three Months Ended May 1, 2026 May 2, 2025 (in millions, except per share amounts) Revenues $ 1,906 $ 1,877 Cost of revenues 1,657 1,668 Selling, general and administrative expenses 83 89 Other operating (income) expense ( 13 ) ( 1 ) Operating income 179 121 Interest expense, net 33 30 Other (income) expense, net 1 5 Income before income taxes 145 86 Income tax (expense) benefit ( 30 ) ( 18 ) Net income $ 115 $ 68 Earnings per share: Basic $ 2.63 $ 1.43 Diluted $ 2.61 $ 1.42 See accompanying notes to condensed consolidated financial statements. -1- Table of Conten ts SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Three Months Ended May 1, 2026 May 2, 2025 (in millions) Net income $ 115 $ 68 Other comprehensive (loss) income, net of tax: Defined benefit obligation adjustment ( 1 ) — Net unrealized (loss) gain on derivative instruments — ( 1 ) Total other comprehensive (loss) income, net of tax ( 1 ) ( 1 ) Comprehensive income $ 114 $ 67 See accompanying notes to condensed consolidated financial statements. -2- Table of Conten ts SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) May 1, 2026 January 30, 2026 (in millions) ASSETS Current assets: Cash and cash equivalents $ 109 $ 182 Receivables, net 962 853 Prepaid expenses 102 122 Other current assets 26 22 Total current assets 1,199 1,179 Goodwill 2,944 2,944 Intangible assets, net 729 761 Property, plant, and equipment (net of accumulated depreciation of $ 221 million and $ 215 million at May 1, 2026 and January 30, 2026, respectively) 111 110 Operating lease right of use assets 184 193 Other assets 171 167 Total assets $ 5,338 $ 5,354 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 634 $ 500 Accrued payroll and employee benefits 278 316 Other accrued liabilities 99 147 Debt, current portion 26 19 Total current liabilities 1,037 982 Debt, net of current portion 2,460 2,468 Operating lease liabilities 189 198 Deferred income taxes 125 104 Other long-term liabilities 104 102 Commitments and contingencies (Note 11) Equity: Common stock, $ 0.0001 par value, 1 billion shares authorized, 43 million and 44 million shares issued and outstanding as of May 1, 2026 and January 30, 2026, respectively — — Additional paid-in capital — — Retained earnings 1,416 1,492 Accumulated other comprehensive income 7 8 Total stockholders' equity 1,423 1,500 Total liabilities and stockholders' equity $ 5,338 $ 5,354 See accompanying notes to condensed consolidated financial statements. -3- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) Shares of common stock Additional paid-in capital Retained earnings Accumulated other comprehensive income (loss) Total (in millions) Balance at January 30, 2026 44 $ — $ 1,492 $ 8 $ 1,500 Net income — — 115 — 115 Issuances of stock 1 5 — — 5 Other comprehensive loss, net of tax — — — ( 1 ) ( 1 ) Cash dividends of $ 0.37 per share — — ( 16 ) — ( 16 ) Stock-based compensation, net of shares withheld for taxes (1) — ( 4 ) — — ( 4 ) Repurchases of stock ( 2 ) ( 1 ) ( 175 ) — ( 176 ) Balance at May 1, 2026 43 $ — $ 1,416 $ 7 $ 1,423 Balance at January 31, 2025 48 $ — $ 1,565 $ 12 $ 1,577 Net income — — 68 — 68 Issuances of stock — 6 — — 6 Other comprehensive loss, net of tax — — — ( 1 ) ( 1 ) Cash dividends of $ 0.37 per share — — ( 18 ) — ( 18 ) Stock-based compensation, net of shares withheld for taxes (1) — ( 2 ) — — ( 2 ) Repurchases of stock ( 1 ) ( 4 ) ( 121 ) — ( 125 ) Balance at May 2, 2025 47 $ — $ 1,494 $ 11 $ 1,505 (1) During the three months ended May 1, 2026 and May 2, 2025, shares withheld for taxes related to stock-based compensation arrangements amounted to $ 17 million. See accompanying notes to condensed consolidated financial statements. -4- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Three Months Ended May 1, 2026 May 2, 2025 (in millions) Cash flows from operating activities: Net income $ 115 $ 68 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 40 36 Stock-based compensation expense 13 15 Deferred income taxes 21 ( 1 ) Gain on sales of investments ( 12 ) — Other ( 2 ) 1 Increase (decrease) resulting from changes in operating assets and liabilities: Receivables ( 109 ) ( 9 ) Prepaid expenses and other current assets 15 6 Accounts payable and other accrued liabilities 85 33 Accrued payroll and employee benefits ( 38 ) ( 51 ) Operating lease assets and liabilities, net ( 1 ) ( 2 ) Other assets and other long-term liabilities, net — 4 Net cash provided by operating activities 127 100 Cash flows from investing activities: Proceeds from sales of investments 15 — Sales of marketable securities 5 3 Purchases of marketable securities ( 4 ) ( 4 ) Expenditures for property, plant, and equipment ( 9 ) ( 8 ) Contributions to investments ( 6 ) ( 6 ) Net cash provided by (used in) investing activities 1 ( 15 ) Cash flows from financing activities: Stock repurchased and retired or withheld for taxes on equity awards ( 188 ) ( 142 ) Dividend payments to stockholders ( 17 ) ( 19 ) Principal payments on borrowings ( 1 ) ( 689 ) Proceeds from borrowings — 750 Issuances of stock 5 6 Net cash used in financing activities ( 201 ) ( 94 ) Net decrease in cash, cash equivalents and restricted cash ( 73 ) ( 9 ) Cash, cash equivalents and restricted cash at beginning of period 190 64 Cash, cash equivalents and restricted cash at end of period $ 117 $ 55 See accompanying notes to condensed consolidated financial statements. -5- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Note 1—Business Overview and Summary of Significant Accounting Policies: Overview Science Applications International Corporation (collectively, with its consolidated subsidiaries, the “Company") is a leading provider of technical, engineering, and information technology ("IT") services primarily to the U.S. government. The Company integrates emerging technology securely and in real-time into mission critical operations that modernize and enable national imperatives. The Company provides these services for large, complex projects with a targeted emphasis on higher-end, differentiated technology services and solutions that accelerate and transform secure and resilient digital environments through system development, modernization, integration, and sustainment to drive enterprise and mission outcomes. Effective January 31, 2026, the first day of fiscal 2027, the Company completed a business reorganization that consolidated its five previous business groups into three . The reorganization was designed to simplify the Company's organization structure and optimize operations and customer focus for growth. The consolidated business groups will be led by three Executive Vice Presidents. The three business groups will continue to report directly to the Company’s Chief Executive Officer (“CEO”), the chief operating decision maker (“CODM”). The reorganization did not have an impact on the Company's reportable segments. The Company now has three customer facing business groups which are also its operating segments. They are aggregated into two reportable segments for financial reporting purposes given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Company’s two reportable segments are the Defense and Intelligence segment and the Civilian segment. The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the Department of War ("DoW", formerly referred to as the Department of Defense) and the Intelligence Community of the United States Government, supporting a variety of missions across land, sea, air, and space. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments. This includes integrating solutions into a spectrum of public service missions that impact travel, security, trade, health and the economy. The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives. These services include end-to-end solutions spanning the design, development, integration, deployment, management, operation, sustainment, and security of customer hardware and software platforms. The Company's Solutions and Technology Group ("STG") supports the operating segments by developing enterprise-class solutions to meet complex customer needs and accelerate digital transformation. These capabilities are delivered to the Company's customers as stand-alone solutions, or integrated with the Company's product offerings through the operations of the business. The STG includes teams focused on artificial intelligence, application development, network services, platforms and cloud, engineering, and cybersecurity. It uses a highly automated, cloud-hosted tool set to rapidly build, test, deploy, and continuously enhance solutions. Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate activities. See Note 10—Business Segments Information for additional information. Principles of Consolidation and Basis of Presentation References to “financial statements” refer to the condensed consolidated financial statements of the Company, which include the statements of income and comprehensive income, balance sheets, statements of equity and statements of cash flows. These financial statements were prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). All intercompany transactions and account balances within the Company have been eliminated. -6- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) The results reported in these financial statements are not necessarily indicative of results that may be expected for the entire year and should be read in conjunction with the information contained in the Company’s Annual Report on Form 10-K for the year ended January 30, 2026. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Significant estimates inherent in the preparation of the financial statements may include, but are not limited to, estimated profitability of long-term contracts, income taxes, fair value measurements, fair value of goodwill and other intangible assets, pension and defined benefit plan obligations, and contingencies. Estimates have been prepared by management on the basis of the most current and best available information at the time of estimation and actual results could differ from those estimates. Reporting Periods The Company utilizes a 52/53 week fiscal year ending on the Friday closest to January 31, with fiscal quarters typically consisting of 13 weeks. Fiscal 2027 began on January 31, 2026 and ends on January 29, 2027, while fiscal 2026 began on February 1, 2025 and ended on January 30, 2026. Operating Cycle The Company’s operating cycle may be greater than one year and is measured by the average time intervening between the inception and the completion of contracts. Investments in Equity Securities The Company invests in certain companies that advance or develop new technologies applicable to its business. Each investment is evaluated for consolidation under the variable interest entities model and/or the voting interest model. As of May 1, 2026, none of the Company's investments in equity securities were consolidated. On April 20, 2026, the Company sold all of its equity in one of its investments, which resulted in a gain of $ 12 million recognized within "Other operating (income) expense" on the condensed consolidated statements of income and $ 15 million in cash proceeds, recognized within "Proceeds from sales of investments" on the condensed consolidated statements of cash flows. Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported on the condensed consolidated balance sheets for the periods presented: May 1, 2026 January 30, 2026 (in millions) Cash and cash equivalents $ 109 $ 182 Restricted cash included in other current assets 3 3 Restricted cash included in other assets 5 5 Cash, cash equivalents and restricted cash $ 117 $ 190 Accounting Standards Updates Accounting Standards Updates Recently Issued But Not Yet Adopted In November 2024, the FASB issued ASU No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The standard includes new disclosure requirements relating to specified categories of expenses (purchases of inventory, -7- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) employee compensation, depreciation, and amortization) that are included in certain expense captions presented on the face of the income statement. Early adoption is permitted. The amendments can be applied on a prospective or retrospective basis. In January 2025, the FASB clarified the effective date of the standard by issuing ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The standard is effective for fiscal years beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adoption of this standard on its financial statement disclosures. In September 2025, the FASB issued ASU No. 2025-06, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The standard modernizes the accounting for internal-use software costs by removing all references to project stages and defining a probable-to-complete threshold to begin capitalizing costs. The standard also clarifies the disclosure requirements for capitalized internal-use software costs. The standard is effective for annual reporting periods, including interim reporting periods within those annual reporting periods, beginning after December 15, 2027. The amendment can be applied prospectively, retrospectively, or on a modified transition approach. Early adoption is permitted. The Company is currently evaluating the impact of adoption of this standard on its consolidated financial statements and related disclosures. Note 2—Earnings Per Share, Share Repurchases and Dividends: Earnings Per Share ("EPS") Basic EPS is computed by dividing net income by the basic weighted-average number of shares outstanding. Diluted EPS is computed similarly to basic EPS, except the weighted-average number of shares outstanding is increased to include the dilutive effect of outstanding stock-based awards. The dilutive effect of outstanding stock-based awards is computed using the treasury stock method. The following table provides a reconciliation of the weighted-average number of shares outstanding used to compute basic and diluted EPS for the periods presented: Three Months Ended May 1, 2026 May 2, 2025 (in millions) Basic weighted-average number of shares outstanding 43.7 47.6 Dilutive common share equivalents - stock options and other stock-based awards 0.3 0.2 Diluted weighted-average number of shares outstanding 44.0 47.8 Antidilutive stock awards excluded from the weighted-average number of shares outstanding used to compute diluted EPS for the three months ended May 1, 2026 and May 2, 2025 were immaterial . Share Repurchases The Company may repurchase shares in accordance with established repurchase plans. The Company retires its common stock upon repurchase with the excess over par value allocated to additional paid-in capital. When repurchases for the period exceed total additional paid-in capital, the excess repurchases are recorded as a reduction to retained earnings. The Company has not made any material purchases of common stock other than in connection with its established share repurchase plans. During the three months ended May 1, 2026, the Company repurchased approximately 1.9 million shares of its common stock from the open market under its existing share repurchase plan for approximately $ 175 million. In December 2024, the Company's Board of Directors authorized the repurchase of up to $ 1.2 billion of the Company's outstanding common stock under its existing share repurchase plan. As of May 1, 2026, the Company has repurchased approximately 30.4 million shares of its common stock under the plan for approximately $ 2.7 billion, which included amounts previously authorized under the plan prior to December 2024. -8- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Dividends The Company declared and paid a quarterly dividend of $ 0.37 per share of its common stock during the three months ended May 1, 2026. Subsequent to the end of the quarter, on May 28, 2026, the Company's Board of Directors declared a quarterly dividend of $ 0.37 per share of the Company's common stock payable on July 24, 2026 to stockholders of record on July 10, 2026. Note 3—Revenues: Changes in Estimates on Contracts Changes in estimates of revenues, cost of revenues or profits related to performance obligations satisfied over time are recognized in operating income in the period in which such changes are made for the inception-to-date effect of the changes. Changes in these estimates can occur routinely over the performance period for a variety of reasons, which include: changes in scope; changes in cost estimates due to unanticipated cost growth or reassessments of risks impacting costs; changes in the estimated transaction price, such as variable amounts for incentive or award fees; and performance being better or worse than previously estimated. A significant portion of the Company's contracts recognize revenue on performance obligations using a cost input measure (cost-to-cost), which requires estimates of total costs at completion. In cases when total expected costs exceed total estimated revenues for a performance obligation, the Company recognizes the total estimated loss in the quarter identified. Total estimated losses are inclusive of any unexercised options that are probable of award, only if they increase the amount of the loss. Aggregate net changes in estimates on contracts accounted for using the cost-to-cost method of accounting were recognized in operating income as follows: Three Months Ended May 1, 2026 May 2, 2025 (in millions, except per share amounts) Net favorable (unfavorable) adjustments $ 8 $ ( 2 ) Net favorable (unfavorable) adjustments, after tax 6 ( 2 ) Basic and Diluted EPS impact $ 0.14 $ ( 0.04 ) Revenues were $ 3 million higher for the three months ended May 1, 2026 and were unchanged for the three months ended May 2, 2025, due to net revenue recognized from performance obligations satisfied in prior periods. -9- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Disaggregation of Revenues The Company's revenues are generated primarily from long-term contracts with the U.S. government including subcontracts with other contractors engaged in work for the U.S. government. The Company disaggregates revenues by customer, contract type and prime versus subcontractor to the federal government for each of its reportable segments. Disaggregated revenues by customer were as follows: Three Months Ended May 1, 2026 May 2, 2025 Defense and Intelligence Civilian Total SAIC Defense and Intelligence Civilian Total SAIC (in millions) Department of War $ 981 $ 1 $ 982 $ 982 $ 3 $ 985 Intelligence and other federal government agencies 479 396 875 445 408 853 Commercial, state and local governments and international 6 43 49 6 33 39 Total $ 1,466 $ 440 $ 1,906 $ 1,433 $ 444 $ 1,877 Disaggregated revenues by contract type were as follows: Three Months Ended May 1, 2026 May 2, 2025 Defense and Intelligence Civilian Total SAIC Defense and Intelligence Civilian Total SAIC (in millions) Cost reimbursement $ 1,164 $ 8 $ 1,172 $ 1,134 $ 20 $ 1,154 Time and materials ("T&M") 138 306 444 141 292 433 Firm-fixed price ("FFP") 164 126 290 158 132 290 Total $ 1,466 $ 440 $ 1,906 $ 1,433 $ 444 $ 1,877 Disaggregated revenues by prime versus subcontractor were as follows: Three Months Ended May 1, 2026 May 2, 2025 Defense and Intelligence Civilian Total SAIC Defense and Intelligence Civilian Total SAIC (in millions) Prime contractor to federal government $ 1,339 $ 371 $ 1,710 $ 1,299 $ 372 $ 1,671 Subcontractor to federal government 121 26 147 128 39 167 Other 6 43 49 6 33 39 Total $ 1,466 $ 440 $ 1,906 $ 1,433 $ 444 $ 1,877 -10- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Contract Balances Contract balances for the periods presented were as follows: Balance Sheet line item May 1, 2026 January 30, 2026 (in millions) Billed and billable receivables, net (1) Receivables, net $ 554 $ 490 Contract assets - unbillable receivables Receivables, net 408 363 Contract assets - unbillable receivables Other assets 22 23 Contract assets - contract retentions Other assets 18 18 Contract liabilities - current Other accrued liabilities 36 41 Contract liabilities - non-current Other long-term liabilities $ 2 $ 2 (1) Net of allowance of $ 2 million as of May 1, 2026 and January 30, 2026. During the three months ended May 1, 2026 and May 2, 2025, the Company recognized revenues of $ 18 million and $ 17 million relating to amounts that were included in the opening balance of contract liabilities as of January 30, 2026 and January 31, 2025, respectively. Remaining Performance Obligations Remaining performance obligations ("RPO") represent the transaction price of exercised contracts (both funded and unfunded) less inception to date revenue recognized. RPO does not include unexercised option periods and future task orders expected to be awarded under IDIQ contracts. As of May 1, 2026, the Company had approximately $ 6.6 billion of RPO. The Company expects to recognize revenue on approximately 76 % of the RPO over the next 12 months and approximately 90 % over the next 24 months, with the remaining recognized thereafter. Note 4—Acquisitions: Acquisition of SilverEdge Government Solutions (“SilverEdge”) On October 15, 2025, the Company acquired SilverEdge, an innovative provider of mission-driven technology solutions and products, for a preliminary purchase price of $ 203 million, net of $ 6 million cash acquired, subject to post-closing adjustments. The acquisition advances the Company's strategy to provide mission focused, IP-based solutions and commercial products to its customers. The Company funded the transaction from increased borrowings and cash on hand. As of May 1, 2026, the Company has substantially completed the purchase price allocation related to this acquisition, primarily subject to the finalization of working capital adjustments. The Company has preliminarily recorded goodwill and amortizable intangible assets of $ 93 million and $ 101 million, respectively. Substantially all of the goodwill recorded is tax deductible. The goodwill is primarily associated with intellectual capital and an acquired assembled workforce. The intangible assets consist of customer relationships of $ 90 million, developed technology of $ 9 million, and backlog of $ 2 million that will be amortized over a period of ten years, eight years, and one year, respectively. During the three months ended May 1, 2026, revenues of $ 19 million related to SilverEdge were recorded to the Defense and Intelligence reportable segment. -11- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Note 5—Goodwill and Intangible Assets: Goodwill The following table presents the carrying value of goodwill by reportable segment: May 1, 2026 January 30, 2026 (in millions) Defense and Intelligence $ 2,094 $ 2,094 Civilian 850 850 Total $ 2,944 $ 2,944 Goodwill is not amortized, but rather tested for potential impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The goodwill impairment test is performed at the reporting unit level. As a result of the internal reorganization on January 31, 2026, the Company reallocated its goodwill to its three new goodwill reporting units. The Company performed a goodwill impairment test immediately before and after the reorganization, both of which resulted in no impairment. For the goodwill impairment test immediately after the reorganization, the Company performed a quantitative assessment of its goodwill as of January 31, 2026 for its three new goodwill reporting units. The Company estimated the fair value of each reporting unit using a 50:50 weighting of fair values derived from an income approach and market approach. Under the income approach, the Company estimated the fair value of its reporting units using a multi-year discounted cash flow model involving assumptions about projected future revenue growth, operating margins, income tax rates, capital expenditures, discount rate, and terminal value. Under the market approach, the Company estimated the fair value of its reporting units based on multiples of earnings derived from observable market data of comparable public companies. Intangible Assets Intangible assets, all of which were finite-lived, consisted of the following: May 1, 2026 January 30, 2026 Gross carrying value Accumulated amortization Net carrying value Gross carrying value Accumulated amortization Net carrying value (in millions) Customer relationships $ 1,551 $ ( 835 ) $ 716 $ 1,551 $ ( 804 ) $ 747 Developed technology 19 ( 7 ) 12 19 ( 6 ) 13 Backlog 2 ( 1 ) 1 2 ( 1 ) 1 Total intangible assets $ 1,572 $ ( 843 ) $ 729 $ 1,572 $ ( 811 ) $ 761 Amortization expense related to intangible assets was $ 32 million and $ 29 million for the three months ended May 1, 2026 and May 2, 2025, respectively. There were no intangible asset impairment losses during the periods presented. -12- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) As of May 1, 2026, the estimated future annual amortization expense related to intangible assets is as follows: Fiscal Year (in millions) Remainder of 2027 $ 94 2028 108 2029 108 2030 105 2031 98 Thereafter 216 Total $ 729 Actual amortization expense in future periods could differ from these estimates as a result of future acquisitions, divestitures, impairments, and other factors. Note 6—Income Taxes: The Company's effective income tax rate was 20.9 % and 20.6 % for the three months ended May 1, 2026 and May 2, 2025, respectively. The rate for both periods was below the Company's combined federal and state statutory tax rate, primarily due to research and development tax credits and the tax deduction for foreign-derived deduction eligible income. Note 7—Debt Obligations: The Company’s debt as of the dates presented was as follows: May 1, 2026 January 30, 2026 Stated interest rate Effective interest rate Principal Unamortized debt issuance costs Net Principal Unamortized debt issuance costs Net (dollars in millions) Term Loan A Facility due September 2030 4.90 % 4.98 % $ 1,100 $ ( 3 ) $ 1,097 $ 1,100 $ ( 3 ) $ 1,097 Term Loan B3 Facility due February 2031 5.40 % 5.54 % 500 ( 3 ) 497 501 ( 3 ) 498 Senior Notes due April 2028 4.88 % 5.11 % 400 ( 2 ) 398 400 ( 2 ) 398 Senior Notes due November 2033 5.88 % 6.09 % 500 ( 6 ) 494 500 ( 6 ) 494 Total debt $ 2,500 $ ( 14 ) $ 2,486 $ 2,501 $ ( 14 ) $ 2,487 Less current portion 26 — 26 19 — 19 Total debt, net of current portion $ 2,474 $ ( 14 ) $ 2,460 $ 2,482 $ ( 14 ) $ 2,468 As of May 1, 2026, the Company had a $ 2.6 billion secured credit facility (the "Credit Facility") consisting of a Term Loan A Facility due September 2030, a Term Loan B3 Facility due February 2031 (together, the "Term Loan Facilities"), and a $ 1.0 billion Revolving Credit Facility due September 2030 (the "Revolving Credit Facility"). During the three months ended May 1, 2026, the Company made a scheduled principal payment of $ 1 million on the Term Loan B3 Facility due February 2031. During the three months ended May 1, 2026, the Company made no borrowings or repayments under the Revolving Credit Facility, and as of May 1, 2026 and January 30, 2026, there were no borrowings outstanding. As of May 1, 2026, the Company was in compliance with the covenants under its Credit Facility. -13- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) As of May 1, 2026 and January 30, 2026, the carrying value of the Company’s outstanding debt obligations approximated its fair value. The fair value of debt is calculated using Level 2 inputs, based on interest rates available for debt with terms and maturities similar to the Company’s Term Loan Facilities and Senior Notes. Maturities of debt as of May 1, 2026 are: Fiscal Year Total (in millions) Remainder of 2027 $ 18 2028 31 2029 489 2030 88 2031 899 Thereafter 975 Total principal payments $ 2,500 Note 8—Changes in Accumulated Other Comprehensive Income (Loss) by Component: The following table presents the changes in accumulated other comprehensive income (loss) attributable to the Company’s fixed interest rate swap cash flow hedges and the Company's defined benefit plans. Defined Benefit Obligation Adjustment (1) Unrealized Gains (Losses) on Fixed Interest Rate Swap Cash Flow Hedges (2) Total (in millions) Three months ended May 1, 2026 Balance at January 30, 2026 $ 8 $ — $ 8 Other comprehensive income before reclassifications — — — Amounts reclassified from accumulated other comprehensive income ( 1 ) — ( 1 ) Income tax impact — — — Net other comprehensive loss ( 1 ) — ( 1 ) Balance at May 1, 2026 $ 7 $ — $ 7 Three months ended May 2, 2025 Balance at January 31, 2025 $ 8 $ 4 $ 12 Other comprehensive income before reclassifications — — — Amounts reclassified from accumulated other comprehensive income — ( 2 ) ( 2 ) Income tax impact — 1 1 Net other comprehensive loss — ( 1 ) ( 1 ) Balance at May 2, 2025 $ 8 $ 3 $ 11 (1) The amount reclassified from accumulated other comprehensive income (loss) is included in "Other (income) expense, net." (2) The amount reclassified from accumulated other comprehensive income (loss) is included in "Interest expense, net. " -14- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Note 9—Sales of Receivables: The Company has a Master Accounts Receivable Purchase Agreement ("MARPA Facility") for the sale of up to a maximum amount of $ 300 million of certain designated eligible receivables with the U.S. government. MARPA Facility activity consisted of the following: Three Months Ended May 1, 2026 May 2, 2025 (in millions) Beginning balance $ 164 $ 164 Sale of receivables 814 1,243 Cash collections ( 814 ) ( 1,107 ) Outstanding balance sold (1) 164 300 Cash collected, not remitted (2) ( 48 ) ( 109 ) Remaining sold receivables (3) $ 116 $ 191 (1) For the three months ended May 1, 2026, there was no net impact to cash flows from operating activities from sold receivables. For the three months ended May 2, 2025, the Company recorded a net increase of $ 136 million to cash flows from operating activities from sold receivables. (2) The Cash collected, not remitted balance is included in "Accounts payable" on the condensed consolidated balance sheets. (3) The Remaining sold receivables balance is included in "Receivables, net" on the condensed consolidated balance sheets. Note 10—Business Segments Information: Effective January 31, 2026, the first day of fiscal 2027, the Company completed a business reorganization that consolidated its five previous business groups into three . The reorganization was designed to simplify the Company's organization structure and optimize operations and customer focus for growth. The consolidated business groups will be led by three Executive Vice Presidents. The three business groups will continue to report directly to the Company’s CEO, the CODM. The reorganization did not have an impact on the Company's reportable segments. The Company now has three customer facing business groups which are also its operating segments. They are aggregated into two reportable segments for financial reporting purposes given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Company’s two reportable segments are the Defense and Intelligence segment and the Civilian segment. The Company defines its operating segments based on the way the CODM manages the operations for the purpose of allocating resources and assessing performance. The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the DoW and the Intelligence Community of the United States Government, supporting a variety of missions across land, sea, air, and space. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments. This includes integrating solutions into a spectrum of public service missions that impact travel, security, trade, health and the economy. The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives. These services include end-to-end solutions spanning the design, development, integration, deployment, management, operation, sustainment, and security of customer hardware and software platforms. Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate. -15- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) The CODM reviews and evaluates segment operating performance using segment "Revenues" and "Adjusted operating income (loss)". Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions and activities that the Company does not consider to be indicative of its ongoing operating performance. Adjusted operating income is calculated by taking operating income and excluding depreciation and amortization, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. The CODM uses revenues and adjusted operating income to assess the financial performance of each operating segment against pre-established performance targets and to allocate resources for strategic business decisions, including investments in certain products or services, potential acquisitions or divestitures, and capital deployment. Labor base is the significant expense that is regularly provided to the CODM, and primarily includes direct labor on customer contracts. The segment information for the periods presented was as follows: Three Months Ended May 1, 2026 Defense and Intelligence Civilian Corporate Total SAIC (in millions) Revenues $ 1,466 $ 440 $ — $ 1,906 Labor base 436 128 — 564 Other operating expenses (income) (1) 884 244 ( 7 ) 1,121 Adjusted operating income (loss) $ 146 $ 68 $ 7 $ 221 Three Months Ended May 2, 2025 Defense and Intelligence Civilian Corporate Total SAIC (in millions) Revenues $ 1,433 $ 444 $ — $ 1,877 Labor base 431 133 — 564 Other operating expenses (income) (1) 887 259 9 1,155 Adjusted operating income (loss) $ 115 $ 52 $ ( 9 ) $ 158 (1) "Other operating expenses (income)" includes cost of revenues, selling, general and administrative expenses, and other operating income or expenses which are not regularly provided to the CODM. This excludes labor base which is presented separately. -16- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) The table below includes a reconciliation of total "Adjusted operating income" to "Income before income taxes" for the three months ended May 1, 2026 and May 2, 2025. Three Months Ended May 1, 2026 May 2, 2025 (in millions) Adjusted operating income $ 221 $ 158 Depreciation of property, plant, and equipment 8 7 Amortization of intangible assets 32 29 Acquisition, integration, restructuring and impairment costs 2 3 Recovery of acquisition, integration, restructuring and impairment costs (1) ( 1 ) ( 2 ) Costs related to the settlement of federal tax audits 1 — Interest expense, net 33 30 Other (income) expense, net 1 5 Income before income taxes $ 145 $ 86 (1) Adjustment reflects the portion of acquisition, integration, restructuring and impairment costs recovered through the Company's indirect rates in accordance with U.S. government Cost Accounting Standards. Asset information by segment is not a key measure of performance used by the CODM. Note 11—Legal Proceedings and Other Commitments and Contingencies: Legal Proceedings The Company is involved in various claims and lawsuits arising in the normal conduct of its business, none of which the Company’s management believes, based on current information, is expected to have a material adverse effect on the Company’s financial position, results of operations or cash flows. In April 2022 and October 2023, the Company received Federal Grand Jury Subpoenas in connection with a criminal investigation being conducted by the U.S. Department of Justice, Antitrust Division ("DOJ"). As required by the subpoenas, the Company has provided the DOJ with a broad range of documents related to the investigation, and the Company’s collection and production process remains ongoing. The Company is fully cooperating with the investigation. At this time, it is not possible to determine whether the Company will incur, or to reasonably estimate the amount of, any fines, penalties or further liabilities in connection with the investigation pursuant to which the subpoenas were issued. Government Investigations, Audits and Reviews The Company is routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect, in particular, to its role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. U.S. government agencies, including the Defense Contract Audit Agency ("DCAA"), the Defense Contract Management Agency and others, routinely audit and review a contractor’s performance on government contracts, indirect rates and pricing practices, and compliance with applicable contracting and procurement laws, regulations and standards. They also review the adequacy of the contractor’s compliance with government standards for its business systems. Adverse findings in these investigations, audits, or reviews can lead to criminal, civil or administrative proceedings, and the Company could face disallowance of previously billed costs, penalties, fines, compensatory damages and suspension or debarment from doing business with governmental agencies. Due to the Company’s reliance on government contracts, adverse findings could also have a material impact on the Company’s business, including its financial position, results of operations and cash flows. -17- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) The indirect cost audits by the DCAA of the Company’s business remain open for certain prior years and the current year. Although the Company has recorded contract revenues based on an estimate of costs that the Company believes will be approved on final audit, the Company does not know the outcome of any ongoing or future audits. If future completed audit adjustments exceed the Company’s reserves for potential adjustments, the Company’s profitability could be materially adversely affected. As of May 1, 2026, the Company believes it has adequately reserved for estimated net amounts to be refunded to customers for potential adjustments for indirect cost audits and compliance with U.S. government Cost Accounting Standards. Letters of Credit and Surety Bonds The Company has outstanding obligations relating to letters of credit of $ 8 million as of May 1, 2026, principally related to guarantees on insurance policies. The Company also has outstanding obligations relating to surety bonds of $ 19 million, principally related to performance and payment bonds on the Company’s contracts. -18- Table of Contents SCIENCE APPLICATIONS INTERNATIONAL CORPORATION